SHANGHAI – [Feb. 3rd, 2015] – ChemPartner, a leading science-driven, technology-based, high-quality preclinical research partner for healthcare companies around the world, recently expanded its global footprint with the establishment of a 24,000 square foot, state-of-the-art research facility in South San Francisco. ChemPartner is the service division of the ShangPharma group.
“We are very excited to announce the opening of ChemPartner’s new state-of-the-art research facility in South San Francisco, one of the global centers of innovation in life science,” said ChemPartner founder and CEO Michael Hui.
“In drug discovery, scientific excellence is the key to success,” Mr.Hui continued. “By taking the CRO service business to the next level, this new facility will help enable our customers, partners, and business collaborators to interrogate the most complex of drug discovery projects.”
ChemPartner’s new research facility will be staffed by experienced drug research scientists from leading biotechnology companies who will collaborate closely with ChemPartner’s scientists based in China.
“In addition to proximity to the top industry talent, the new facility brings ChemPartner services closer to the biopharmaceutical communities in the US, and will enable us to develop more innovative ways to bring value to our partners.”
The Company noted that the new facility is the first step in a planned build-out of ChemPartner’s research presence in major innovation hubs around the world.
About ChemPartner & ShanghPharma:
The service division of the ShangPharma group, ChemPartner, is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. The company offers a broad range of high-quality, integrated services across the drug discovery and development process to pharmaceutical and biotechnology companies around the globe. ChemPartner’s services consist of discovery biologics, discovery chemistry, discovery biology and preclinical development, pharmaceutical development, small molecule and biologics manufacturing services.
With the mission of providing and developing cutting edge science and technology to help its partners develop important new therapies, the ShangPharma Group includes divisions wholly focused on enabling new technologies (‘ShangPharma Technologies’) and investing in early stage ideas (‘ShangPharma Investments’) that provide the innovative foundations for future drug therapies.
ShangPharma aims, through all its divisions, to create an ecosystem to allow close interaction between major hospitals and academic centers, by matching them with pharma, biotech, and research institutes it can enable the success of all. The group is actively investing, licensing, and forming partnerships to better serve the healthcare industry.
